Abstract | BACKGROUND: OBJECTIVE: Our aim was to investigate its efficacy in POD. STUDY DESIGN: Single-centre, randomized, double-blind, vehicle-controlled study including 40 POD patients with a 4-week treatment and a 4-week follow-up. Efficacy was assessed by a novel Perioral Dermatitis Severity Index (PODSI) and Finlay's Dermatology Life Quality Index (DLQI). SETTING: Outpatient clinics of a large dermatological hospital in Munich, Germany. RESULTS: During treatment, the PODSI was significantly lower in the pimecrolimus group compared with vehicle (P = 0.005-0.02) whereas at follow-up, no significant differences were observed. At week 2, the responder rates (> or = 50% PODSI improvement) were 50% with pimecrolimus cream (1%) and 25% with vehicle (P = 0.095). DLQI was improved in pimecrolimus group compared with vehicle. CONCLUSION: Results suggest that pimecrolimus cream (1%) effectively treats acute-stage POD.
|
Authors | T Oppel, T Pavicic, S Kamann, M Bräutigam, A Wollenberg |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 21
Issue 9
Pg. 1175-80
(Oct 2007)
ISSN: 0926-9959 [Print] England |
PMID | 17894701
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dermatologic Agents
- pimecrolimus
- Tacrolimus
|
Topics |
- Administration, Topical
- Adolescent
- Adult
- Aged
- Dermatitis, Perioral
(drug therapy)
- Dermatologic Agents
(administration & dosage, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Quality of Life
- Severity of Illness Index
- Statistics, Nonparametric
- Tacrolimus
(administration & dosage, analogs & derivatives, therapeutic use)
- Treatment Outcome
|